The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.12, Iss.1, 2012-01, pp. : 63-77

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 – 17 years

By Mitchell Ruth Trück Johannes Pollard Andrew J

Expert Opinion on Biological Therapy, Vol. 13, Iss. 10, 2013-10 ,pp. : 1451-1465

Informa Healthcare

Access to resources Recommend Favorite

Defensins - Non-antibiotic Use for Vaccine Development

Current Protein and Peptide Science, Vol. 6, Iss. 1, 2005-02 ,pp. : 53-60

Bentham Science Publishers

Access to resources Recommend Favorite

Meningococcal serogroup C conjugate vaccine

By Lakshman Raman Finn Adam

Expert Opinion on Biological Therapy, Vol. 2, Iss. 1, 2002-01 ,pp. : 87-96

Informa Healthcare

Access to resources Recommend Favorite

Escherichia coli-Polysaccharide-Protein Conjugate Vaccine

By Cryz

Enzyme and Microbial Technology, Vol. 17, Iss. 8, 1995-08 ,pp. : 765-766

Elsevier

Access to resources Recommend Favorite

Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component

By Wetter Michael

Glycoconjugate Journal, Vol. 30, Iss. 5, 2013-07 ,pp. : 511-522

Springer Publishing Company

Access to resources Recommend Favorite